Given that Stat3 activity promotes chemotherapy resistance [35,36], and the results that H182 in combination with cisplatin or docetaxel had a synergistic effect against breast cancer cells in vitro (Fig. 6B), we were interested to determine the antitumor efficacy of combining H182 and radiation therapy. The gene discussed is STAT3; the disease is breast carcinoma.